(IN BRIEF) Sandoz has announced a new partnership with Samsung Bioepis to develop and commercialize up to five biosimilar medicines, beginning with a vedolizumab biosimilar targeting inflammatory bowel diseases. The agreement grants Sandoz global commercialization rights in most markets, while … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged affordable medicines, Alexion, biologics, biosimilar pipeline, biosimilars, commercialization agreement, Crohn disease, drug development, eculizumab, Entyvio, Epysqli, global healthcare, inflammatory bowel disease, pharmaceutical partnership, pouchitis, Pyzchiva, Richard Saynor, Samsung Bioepis, Sandoz, Sandoz and Samsung Bioepis Deepen Alliance to Capture Growing Biosimilar Market Opportunity Worldwide, Sandoz Secures Global Commercialization Rights in New Biosimilar Agreement with Samsung Bioepis, Soliris, Takeda, Ulcerative colitis, ustekinumab, vedolizumab
(IN BRIEF) The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several other retinal disorders. The therapy has demonstrated comparable efficacy and safety to … Read the full press release
Posted in Business, European Union, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged access to medicines, Afqlir, Basel Switzerland, biosimilars Europe, choroidal neovascularization, diabetic macular edema, diabetic retinopathy, EU commercialization rights, European Commission approval, eye disease treatment, Lucentis reference medicine, lupin, neovascular age-related macular degeneration, ophthalmology treatments, pharmaceutical partnership, ranibizumab biosimilar, Ranluspec, retinal vein occlusion, Sandoz, Sandoz and Lupin Advance European Market Entry for Ranluspec Following Regulatory Clearance, Sandoz Secures European Approval for Ranluspec to Expand Access to Biosimilar Treatment in Retinal Diseases
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?